Medigen Vaccine Biologics Corporation (hereinafter as MVC), a subsidiary of Medigen Biotechnology Corporation, founded in Taiwan in Oct, 2012. With modern cell-cultivation platform and extensive international partnerships, MVC develops novel cell-based vaccines and affordable biosimilars to prevent regional infectious disease in Taiwan and SouthEast Asia.
To ensure adequate supply of high quality vaccines and to produce vaccines locally in Taiwan, MVC established Taiwan’s first cell-based vaccines and biologics manufacturing facility complied with PIC/S GMP standard at Hsinchu Biomedical Science Park. The vaccine plant is also one of the few pharmaceutical plants in Taiwan equipped with biosafety 2+ production lines. MVC aims to become one of the leading pharmaceutical companies for the Asia-Pacific region.